MMD Masterclass: Prof. C. Figdor

Mini Symposium: Immunotherapy: harnessing the immune system to treat disease

26 September 2013 00:00 hrs.
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
The next generation of dendritic cell vaccines

Prof C.G. Figdor, Department of Tumor Immunology, RUNMC, NCMLS, Nijmegen, The Netherlands


Prof. Jolanda de Vries and Prof. Gosse Adema, department of Tumor Immunology, NCMLS

26-09-2013 00:00:00Europe/AmsterdamThe next generation of dendritic cell vaccines Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route

Remarks / more information:

Figdor, CarlTo date, Dendritic Cell (DC)-based immunotherapy is explored worldwide in clinical vaccination trials with cancer patients, predominantly with ex vivo-cultured monocyte- or Cd34+ derived DCs. Although the concept of DC vaccination has been proven, clinical results are limited and it is questionable if monocytes are the best precursor. Therefore, it is attractive to consider alternative DC sources, such as peripheral blood derived DCs. Two major types of naturally occurring DCs circulate in peripheral blood, myeloid DCs (mDCs) and plasmacytoid (pDCs). These DC subsets express different surface molecules and are suggested to have distinct functions. We have recently started to explore these TLR-ligand activated natural blood DCs in clinical trials. Furthermore, I will discuss direct targeting of these DC-subsets in vivo, as another novel treatment modality. The different surface receptors identified on DC subsets together with the distinct TLR expression profiles provides us with a novel toolbox to more precisely explore the therapeutic potential or natural DC in cancer immunotherapy.

<< back to all events